ArticleCancer medicine2026
Clinical Outcomes and Prognostic Factors of Stereotactic Radiotherapy for Spinal Metastases With Epidural Spinal Cord Compression Grades 1-2.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveInvestigate the efficacy of stereotactic radiotherapy in patients with metastatic tumors accompanied by epidural spinal cord compression (ESCC) of Grades 1-2 but without vertebral instability who did not undergo surgery.
methodsBased on lesion volume and spinal cord compression degree, SBRT doses of 24 Gy/1f, 30 Gy/3f, and 40 Gy/5f were given. The primary endpoint was local progression-free survival (LPFS). Secondary endpoints included toxicity and overall survival (OS). A comparative analysis of LPFS outcomes among different ESCC grades was conducted, and multivariate analysis was used to assess factors influencing local treatment efficacy.
resultsAmong 71 lesions, only three showed local progression. No statistically significant difference in LPFS was observed between ESCC Grades 1 and 2 (p = 0.769). Esophagitis/oral mucositis occurred in 15 cases (33.3%), including 1 case of Grade 3 (2.2%). Nausea occurred in 14 cases (19.7%), with 12 cases of Grade 1 (16.9%) and 2 cases of Grade 2 (2.8%). Vomiting occurred in 3 cases (4.2%), with 2 cases of Grade 1 (2.8%) and 1 case of Grade 2 (1.4%). Acute pain occurred in 3 cases (4.2%). One case (1.4%) had late neurological damage of Grade 2, and there were no cases of spinal cord injury. ESCC grading was not a significant factor affecting LPFS in tumor SBRT (p = 0.693).
conclusionPreliminary findings suggest that for ESCC Grades 1-2 metastatic tumor patients who have no vertebral instability, stereotactic radiotherapy alone has outstanding local control and minimal toxicity. SBRT could be an effective alternative to surgery combined with radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.